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Abstract. 
 
Perlecan is a heparan sulfate proteoglycan 
that is expressed in all basement membranes (BMs), in 
cartilage, and several other mesenchymal tissues during 
development. Perlecan binds growth factors and inter-
acts with various extracellular matrix proteins and cell 
adhesion molecules. Homozygous mice with a null mu-
tation in the perlecan gene exhibit normal formation of 
BMs. However, BMs deteriorate in regions with in-
creased mechanical stress such as the contracting myo-
cardium and the expanding brain vesicles showing that 
perlecan is crucial for maintaining BM integrity. As a 
consequence, small clefts are formed in the cardiac 
muscle leading to blood leakage into the pericardial 
cavity and an arrest of heart function. The defects in the 
BM separating the brain from the adjacent mesen-
chyme caused invasion of brain tissue into the overlay-
ing ectoderm leading to abnormal expansion of neu-
roepithelium, neuronal ectopias, and exencephaly. 
Finally, homozygotes developed a severe defect in carti-
lage, a tissue that lacks BMs. The chondrodysplasia is 
characterized by a reduction of the ﬁbrillar collagen 
network, shortened collagen ﬁbers, and elevated ex-
pression of cartilage extracellular matrix genes, suggest-
ing that perlecan protects cartilage extracellular matrix 
from degradation.
Key words: perlecan • basement membrane • cardiac 
muscle • exencephaly • chondrodysplasia
 
P
 
ERLECAN
 
 is a heparan sulfate proteoglycan and a
 
major component of basement membranes (BMs)
 
1
 
and cartilage (Hassell et al., 1980; French et al.,
1999). Although several biochemical and structural prop-
erties of perlecan have been reported, its in vivo function
remains largely unknown. The core protein is composed of
several different sequence motifs that are also found in the
low density lipoprotein receptor and in other extracellular
matrix (ECM) proteins such as laminin and the neural cell
adhesion molecule (Murdoch et al., 1992). The NH
 
2
 
 termi-
nus of perlecan contains three glycosaminoglycan attach-
ment sites (Costell et al., 1997) that are usually modified
by the addition of heparan sulfate side chains.
During mouse development perlecan is first expressed
in two-cell embryos (Dziadek and Timpl, 1985). The ex-
pression of perlecan increases on the external surface of
trophectodermal cells of blastocysts (Smith et al., 1997),
which correlates with the acquisition of attachment com-
petence of blastocysts in vitro. Since perlecan expression is
attenuated during delayed implantation (Smith et al.,
1997) a role for perlecan in the attachment of the embryo
to the uterine epithelium was suggested. During postim-
plantation development, perlecan is detected in blood ves-
sel walls and in the developing heart and skeletal muscle
 
(Handler et al., 1997). In 
 
Caenorhabditis elegans
 
, muta-
tions in the 
 
unc-52
 
 gene, the orthologue of the mammalian
perlecan gene, lead to disruptions of sarcomeres and cause
detachment of body wall muscle (Rogalski et al., 1993), in-
dicating an important role of perlecan for muscle function.
A significant increase in perlecan expression occurs during
organogenesis of the kidney, lung, liver, spleen, gas-
trointestinal tract, and cartilage (Handler et al., 1997). The
levels of perlecan are low in precartilaginous tissues
(French et al., 1999), but are high in mature cartilage. Re-
cent in vitro findings have shown that perlecan supports
chondrocyte differentiation (French et al., 1999), which to-
gether with its expression pattern, suggests a role for this
molecule in skeletogenesis.
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In contrast to the well characterized expression pattern,
only a few functional properties of perlecan are known.
The presence of perlecan in BMs and its ability to interact
with other BM components such as collagen type IV, lami-
nin, and nidogen/entactin in vitro suggested that it is in-
volved in BM assembly (Reinhardt et al., 1993; Hopf et al.,
 
1999). It also binds cell adhesion molecules, such as 
 
b
 
1 and
 
b
 
3 integrins (Hayashi et al., 1992; Brown et al., 1997)
and 
 
a
 
-dystroglycan (Peng et al., 1998; Talts et al., 1999),
and several of these components are also known to partici-
pate in BM assembly (Bloch et al., 1997; Henry and Camp-
bell, 1998; Sasaki et al., 1998).
One property that perlecan shares with several other
proteoglycans is its ability to bind and store growth fac-
tors. The heparan sulfate side chains bind FGF-2 and may
serve as a low affinity coreceptor, thus, playing a role in
FGF-2–mediated mitogenesis and angiogenesis (Aviezer
et al., 1994). The observation that high levels of perlecan
in metastatic melanomas correlate with a more aggressive
phenotype (Timar et al., 1992) supports the latter hypoth-
esis. The core protein is also capable of binding different
growth factors including PDGF-B and FGF-7 (Göhring et
al., 1998; Sharma et al., 1998).
Heparan sulfate proteoglycans are thought to be essen-
tial for the glomerular filtration apparatus. Antibodies
against perlecan core protein destroy the filtering proper-
ties of the glomerular BM and cause proteinuria (Miet-
tinen et al., 1986). Moreover, in long-term diabetes mel-
litus, the content of heparan sulfate proteoglycans is
decreased (Comper et al., 1996), which is believed to con-
tribute to the development of diabetic nephropathy with
characteristic proteinuria and ultimately renal failure. Per-
lecan has also been implicated in the pathogenesis of
Alzheimer’s disease (AD) amyloidosis. A common feature
of AD amyloids is the presence of perlecan within the de-
 
posits (Snow and Wight, 1989) where it interacts with the
 
b
 
-amyloid (A
 
b
 
) protein and its precursor (Castillo et al.,
1997). It seems that this interaction enhances the forma-
tion of A
 
b
 
 fibrils and protects A
 
b
 
 from protease degrada-
tion (Gupta-Bansal et al., 1995).
To directly test the function of perlecan in vivo, we have
generated mice lacking perlecan gene expression. We
demonstrate that perlecan is essential for maintaining the
integrity of cartilage ECM and BMs of contracting cardiac
muscle cells and expanding brain vesicles.
 
Materials and Methods
 
Generation of Perlecan-deficient Mice
 
A 700-bp DNA fragment from the 5
 
9
 
 region of the mouse perlecan cDNA
was used to screen a genomic library derived from a mouse D3/129 embry-
onic stem (ES) cell line (a gift from J.S. Mudgett, Merck Sharp & Dohme,
NJ) to isolate perlecan genomic clones. The targeting construct (see Fig. 1
A) consisted of an 8-kb fragment containing exon 5, an expression cas-
sette flanked by 
 
loxP
 
 sites in which the phosphoglycerate kinase promoter
controls the expression of the neomycin (neo) gene and the Herpes sim-
plex virus thymidine kinase (HSV-tk) gene, respectively, an 0.8-kb frag-
ment containing exon 6 followed by a single 
 
loxP
 
 site and a 1.5-kb frag-
ment containing exon 7 (for more detailed information contact: reinhard.
fassler@pat.lu.se).
The targeting construct was electroporated into R1 ES cells. ES cells
culture, electroporation, isolation, and analysis of G418-resistant ES cell
clones was carried out as described (Fässler and Meyer, 1995). Genomic
DNAs were digested with EcoRI, and probed with an external 3-kb
BamHI-EcoRI genomic DNA fragment (see Fig. 1, probe 1). ES cell
clones that had undergone homologous recombination were transiently
transfected with a 
 
Cre
 
 expression plasmid (a gift from Dr. Werner Müller,
University of Cologne, Germany) and selected in the presence of FIAU.
Surviving ES cell clones were isolated and analyzed by Southern blot by
cleaving genomic DNA with EcoRI, BamHI, or HindIII, respectively, and
probed with an internal genomic DNA fragment (see Fig. 1, probe 2). The
generation of germline chimeras and breeding were carried out as de-
scribed (Fässler and Meyer, 1995).
 
Antibodies
 
The following primary antibodies were used for immunohistochemistry:
rat anti-collagen type II (diluted 1:400; obtained from Dr. Rikard Holm-
dahl, Lund University, Sweden); rabbit anti-collagen type X (1:500; ob-
tained from Dr. Bjorn Olsen, Harvard Medical School, Boston, MA); rab-
 
bit anti–laminin-1 (1:200); rabbit anti–perlecan antibodies against domain I
(1:1,000), domain III-3 (1:500) and domain V (1:1,000); rat anti–nidogen-1
(1:30); mouse anti–
 
b
 
-tubulin isotype III (1:100; Sigma Chemical Co.); rab-
bit anti-nestin (1:2,000; obtained from Dr. Zaal Kokaia, Lund University,
Sweden); mouse anti-reelin (1:1,000; obtained from Dr. André Goffinet,
University of Namur, Belgium); and Ki-67 (1:50; Dianova, Hamburg, Ger-
many).
The following secondary antibodies were used: biotinylated goat anti–
rabbit Ig, biotinylated goat anti–rat Ig (obtained from Vector Laborato-
ries Inc.); FITC-conjugated donkey anti–mouse; and Cy3-conjugated goat
anti–rat (both obtained from Jackson ImmunoResearch Laboratories,
Inc.).
 
Reverse Transcriptase (RT) –PCR Assays, 
Radioimmunoassays, and Northern Blot
 
Total RNA from E12.5 embryos was isolated as described (Fässler and
Meyer, 1995). RT-PCR was carried out with a commercial kit (Titan RT-
PCR; Boehringer Mannheim). The primer sequences were as follows: 5
 
9
 
-
CCCGAATACAGGAAGATCCC-3
 
9
 
 specific for exon 5, and 5
 
9
 
-TCA-
CAGGCGAACTCGTTAGGCTCA-3
 
9
 
 specific for exon 8. The amplifi-
 
cation products were separated on 2% agarose gel, blotted onto nylon
 
filters, and hybridized with a 
 
g
 
-[
 
32
 
P]ATP–labeled oligonucleotide (5
 
9
 
-
CAGACATGTCCCTGCAGTCAGGCC-3
 
9
 
) specific for exon 7.
Confluent ES cells were grown overnight in serum-free medium. The
medium was collected and the cells were lysed with RIPA buffer supple-
mented with proteinase inhibitors (5 mM NEM, 2 mM PMSF, 5 mM
EDTA). Radioimmunoassays were performed with the medium and cell
extract using either tissue-derived (laminin, perlecan) or recombinant pro-
teins (nidogen-1) as reference inhibitors. Two assays specific for perlecan
domains I and III-3 were used and gave similar results (Costell et al.,
1997).
For Northern blotting, cartilage samples were dissected from the limbs
of normal and perlecan-deficient E17.5 embryos, and total RNA was pre-
pared, separated, blotted, and probed as described (Fässler and Meyer,
 
1995). The oligo-labeled probes represented 
 
z
 
500 bp of the mouse
Col2a1, matrilin-3, and cartilage matrix protein (COMP) cDNAs, respec-
tively. Signal intensities were measured from nonsaturated films using a
Gel-ProAnalyzer (Media Cybernetics).
 
Histological Analysis, Immunohistochemistry, and 
Staining of Skeletons
 
For histological analyses, staged embryos were fixed in 4% fresh
paraformaldehyde in PBS overnight, pH 7.2, dehydrated in a graded alco-
hol series, and embedded in paraffin (Paraplast X-tra; Sigma Chemical
Co.). Sections were cut at 6–8 
 
m
 
m and stained with hematoxylin/eosin or
cresyl violet (Nissl staining). To detect proteoglycans and calcification,
bone sections were stained with Safranin orange and van Kossa (Aszódi et
al., 1998). To detect proliferating cells, 5-bromo-2
 
9
 
-deoxyuridine (BrdU;
Sigma Chemical Co.) and anti-BrdU mAb (Boehringer Mannheim) were
used as described (Aszódi et al., 1998). Apoptosis was analyzed by the ter-
minal deoxynucleotidyl transferase (TdT)–mediated dUTP nick end la-
beling (TUNEL) method using a commercial in situ cell death detection
kit (Boehringer Mannheim) according to the manufacturer’s instructions.
For immunohistochemistry, embryos were either fixed in 4% buffered
paraformaldehyde or in 95% ethanol/5% acetic acid overnight at 4
 
8
 
C, em- 
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bedded in paraffin, and sectioned at 6–8 
 
m
 
m. Immunostaining was per-
formed either by using the Vectastain ABC Elite kit (Vector Laborato-
ries) or by using an immunofluorescence method described earlier
(Aszódi et al., 1998). Skeletons of E17.5 embryos were prepared and
stained as described by Aszódi et al. (1998) and photographed on a dis-
secting microscope.
 
Plastic Embedding and Electron Microscopy
 
For light microscopy of heart tissue, 4% paraformaldehyde immersion-
fixed embryos were postfixed with 2% osmium tetroxide in PBS for 2 h at
4
 
8
 
C. After a thorough wash in PBS for 3
 
3 
 
10 min, the embryos were
block-stained with 1% uranyl acetate in 70% ethanol for 8 h. Afterwards
the specimens were dehydrated, infiltrated with and embedded in araldite,
cut with a glass knife (1–2 
 
m
 
m) on a Reichert ultramicrotome (Leica), and
stained with methylene blue. Ultrastructural analysis of basement mem-
branes and cartilage tissue was performed as described earlier (Bloch et al.,
1997; Aszódi et al., 1998).
For scanning electron microscopy, E10.5 embryos were prepared as
previously described (Walter and Müller, 1985) with the modification that
samples were critical point dried in a Balzer critical point dryer using
100% ethanol as the intermediate solvent. Embryos were mounted on alu-
minum holders, sputtered with 60 nm palladium/gold, and examined in a
Jeol JSM-T330 scanning electron microscope. Electron microscopy after
negative staining with anti–laminin-1 antibody with protein A coupled to
colloidal gold was done as described by Roth et al. (1980).
 
Results
 
Targeted Disruption of the Perlecan Gene
 
The perlecan gene was inactivated in ES cells by homolo-
gous recombination using the 
 
cre/loxP
 
 technique. A neo-
mycin/thymidine kinase (neo/tk) cassette flanked by single
 
loxP
 
 sites was inserted into intron 5 and a single 
 
loxP
 
 site
was inserted into intron 6 (Fig. 1 A). Eight independently
targeted ES cell lines were obtained. Two of them (clones
243 and 310) were transiently transfected with a 
 
cre
 
 re-
combinase expression plasmid, selected in FIAU, and ana-
lyzed for 
 
cre
 
-mediated deletion. In three clones derived
from 243 and 1 clone derived from 310, respectively, the
sequence between the outermost 
 
loxP
 
 sites (including the
neo/tk cassette, part of intron 5, exon 6, and part of intron
6) was deleted (Fig. 1 A). One clone carrying the constitu-
tive null allele from 243 and from 310, respectively, was in-
jected into C57BL/6 blastocysts and transferred to pseu-
dopregnant females. Chimeric males from both clones
gave germline transmission of the mutated perlecan gene.
 
ES Cells Carrying a Homozygous Mutation in the 
Perlecan Gene Do Not Secrete Perlecan
 
To verify that the deletion of exon 6 in the perlecan gene
leads to a constitutive null mutation, ES cells carrying a
homozygous mutation were generated. Heterozygous ES
cells were retransfected with the original targeting con-
struct and again selected for neo expression. Afterwards,
one of the clones with a recombination event on the wild-
type allele was transiently transfected with the 
 
cre
 
 expres-
sion plasmid to obtain ES clones with a homozygous dele-
tion of exon 6 (Fig. 1 B).
To test whether the mutant allele was transcribed, RT-
PCR was performed with total RNA extracted from nor-
mal, heterozygous, and homozygous ES cells. The ampli-
fied fragment encompasses sequences in exons 5–8. The
size of the amplified DNA fragment was 640 bp for the
wild-type allele and 479 bp for the mutant allele, indicating
that splicing occurs between exon 5 and 7 (Fig. 1 C). Splic-
ing of exon 5–7 leads to a reading frame shift and to the
formation of a truncated perlecan protein consisting of the
116–NH
 
2
 
-terminal amino acids that make approximately
half of domain I.
To determine whether the mutant mRNA was trans-
lated, normal and homozygous ES cells were grown in se-
rum-free culture medium, and the supernatant as well as
the cell extract were subjected to a highly sensitive RIA
using polyclonal antibodies against laminin-1, nidogen-1,
or the NH
 
2
 
-terminal domain I of perlecan. Whereas nor-
mal and mutant ES cells produce similar amounts of lami-
Figure 1. Targeting strategy, Southern blots,
PCR, and RIA analysis of ES cells and mice
lacking perlecan. (A) Structure of the wild-
type perlecan allele, targeting construct, and
targeted perlecan allele before and after cre-
loxP–mediated deletion. The dark boxes
show exons of the perlecan gene, the open
box shows the neo-tk cassette, and the loxP
sites are indicated as triangles. Probe 1 was
used to detect homologous recombination,
and probe 2 was used to identify the null al-
lele. Restriction sites are as follows: E,
EcoRI; B, BamHI; and H, HindIII. (B)
Southern blot analysis of EcoRI-digested ge-
nomic DNA derived from wild-type, het-
erozygous, and homozygous mutant mice hy-
bridized with probe 1. (C) Detection of
mutant mRNA lacking exon 6 by RT-PCR
using the total RNA prepared from wild-type,
heterozygous, and homozygous ES cells.
Primers from exons 5 and 8 amplified 640 bp
from the wild-type and 479 bp from the mutant allele. PCR products were probed with exon 7–specific radiolabeled oligonucleotide.
(D) Radioimmunoassay measurement of laminin-1, nidogen-1, and perlecan in the serum-free medium derived from wild-type and mu-
tant ES cells. Values are means 6 SD of triplicate culture dishes and are expressed as micrograms per milliliter of supernatant. 
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nin and nidogen-1, only normal but not mutant ES cells
produce perlecan (Fig. 1 D).
These data show that although the mutant perlecan al-
lele is transcribed, no truncated protein could be detected
with a domain I–specific polyclonal antibody. Most likely,
the truncated form of domain I is not properly folded and
is consequently degraded intracellularly as soon as it is
translated. This was confirmed by episomal transfection of
human EBNA-293 cells with domain I lacking 38 COOH-
terminal residues that did not produce any recombinant
fragment (data not shown). Therefore, the mutation in the
perlecan gene is designated as a loss of function mutation.
 
Mice Homozygous for the Perlecan-Null Mutation Die 
at Two Developmental Stages: between E10 and E12 
and Perinatally
 
Mice heterozygous for the mutation appeared normal and
did not display any overt anatomical or behavioral abnor-
malities. No mice homozygous for the mutation were de-
tected among 728 weaned progeny from heterozygous
intercrosses (Table I). Analysis of newborn offspring de-
tected three homozygotes and several cannibalized mice
among 98 neonates (Table I). The three homozygotes
showed exencephaly, chondrodysplasia, hemorrhage in
several organs (see below), severe cleft palates, and died
around birth.
To determine when the remaining homozygotes die, em-
bryos were examined from E9.5 to birth (Table I). At
E9.5, wild-type, heterozygous, and homozygous mutant
embryos were represented in a normal Mendelian ratio
(Table I). Perlecan-null embryos at E9.5 were indistin-
guishable from wild-type and heterozygous littermates.
E9.5 perlecan-null embryos formed brain vesicles, optic
vesicles, branchial arches, otic pits, limb buds, a beating
heart, and 20–25 somites (not shown). Therefore, develop-
ment to E9.5 proceeds normally in the absence of perlecan.
By E10.5, defects began to appear in perlecan-null em-
bryos. Although they were still present in the expected
percentage (Table I) and were of normal size, 
 
z
 
70–80%
were dead as demonstrated by the absence of the heart
 
beating and the presence of severe hemopericardium (Fig.
2 B, arrow). 20–30% of homozygotes were alive and of
normal appearance (not shown). By E11.5 and E12.5 the
percentage of dead embryos with hemopericardium in-
creased further, whereas some of the living embryos devel-
oped abnormally in the head region and survived to the
perinatal period. At all stages analyzed, the placental de-
velopment was unaffected by the loss of perlecan. The
placental size, architecture, and the blood content were
similar between normal and perlecan-null embryos (not
shown). In addition, PECAM whole mount stainings of
E9.5 and E10.5 embryos revealed that homozygotes had
no defects in angiogenesis, sprouting, and remodeling to
generate vessels of different sizes (not shown). At later
stages of development (E13–E17), we could observe the
formation of microaneurysms associated with bleedings in
several tissues including lung, skin, and brain (not shown).
These results indicate that a null mutation in the per-
lecan gene leads to two patterns of development. Many
of the perlecan-null embryos die during an early crisis
(E10.5–E12.5) characterized by hemopericardium and
heart arrest. The few remaining mutants survive to the
perinatal period (Table I), but develop severe brain and
skeletal defects (see below).
 
Early Lethality in Perlecan-deficient Embryos Is Due to 
Myocardial Defects
 
At E10–11, many perlecan-null embryos manifested sev-
eral signs of cardiac insufficiency characterized by intra-
pericardial hemorrhages (Fig. 2 B), weak heartbeats, or car-
diac arrest. To investigate these defects, wild-type and
alive perlecan-null embryos were analyzed by immunohis-
tochemical and ultrastructural methods. The high resolu-
tion analysis of plastic-embedded hearts derived from
E10.5 wild-type embryos showed a continuous wall of sev-
eral layers of cardiomyocytes covered on both sides by a
single cell layer of endothelial cells forming the endocar-
dium and epicardium (Fig. 2, C and E). In a large number
of perlecan-null embryos, the compact layer of cardiomyo-
cytes was interrupted by small intercellular clefts that were
 
Table I. Progeny of Perlecan
 
1
 
/
 
2
 
 
 
3
 
 Perlecan
 
1
 
/
 
2
 
 Crosses
 
Stage No. of litters
Perlecan genotype (%)
 
2
 
/
 
2
 
 Viable
 
†
 
Percentage of expected
 
2
 
/
 
2
 
 progeny
 
§
 
1
 
/
 
11
 
/
 
22
 
/
 
2
 
P21 91 246 (34) 482 (66) 0 0 0
P0 13 32 (33) 63 (64) 3 (3) 0 0
E18.5 4 12 (40) 18 (60) 0 (0) 0 0
E17.5 15 39 (35) 67 (59) 7* (6) 7 20
E16.5 2 6 (40) 8 (53) 1* (7) 1 20
E15.5 6 12 (29) 25 (60) 5* (12) 5 41
E14.5 8 12 (20) 43 (72) 5* (8) 5 28
E13.5 11 23 (26) 60 (68) 5* (6) 5 18
E12.5 15 28 (24) 63 (55) 24* (21) 19 63
E11.5 34 74 (28)  151 (57) 40* (15) 17 23
E10.5 34 78 (29) 138 (50) 56 (21) 53 74
E9.5 11 17 (21) 43 (53) 21 (26) 21 105
 
E, embryonic day; and P, postnatal day.
*Additional embryos deteriorating.
 
†
 
Heart is beating.
 
§
 
Percentage of expected viable 
 
2
 
/
 
2
 
 calculated as a percent if sum of 
 
1
 
/
 
1
 
 
 
1
 
 
 
1
 
/
 
2
 
 
 
5
 
 75%. 
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often covered by an intact layer of endo- and epicardium
(Fig. 2, D and F–H). In a few embryos, the clefts in the
myocardium were filled with endocardial cells (Fig. 2, D
and F). The defects were associated with blood cell leak-
age into the pericardial cavity (Fig. 2, D and F). Adjacent
to the myocardial defects, the pericardial tissue was thick-
ened because of an increase in cell number and matrix
deposition (Fig. 2 D). No defects were observed in the
blood vessels of affected hearts (not shown).
At E9.5, thin and normally appearing BMs were ob-
served around perlecan-null cardiomyocytes (not shown).
However, at E10.5 normal cardiomyocytes were covered
by a continuous BM (Fig. 2 I), whereas perlecan-null car-
diomyocytes lacked BM deposition (Fig. 2 J) or showed
small patches of electron dense material on their cell sur-
face (Fig. 2 K). The formation of sarcomeres (Fig. 2 J) and
tight junctions were normal in perlecan-null cardiomyo-
cytes. Ultrastructural analysis of BMs in other tissues in-
cluding skin (Fig. 2, L and M) and gut (not shown) re-
vealed no abnormalities, suggesting that at E10.5 the BM
defects are restricted to the heart where they are exposed
to mechanical stress. To test whether the BM defects in
the perlecan-null myocardium are associated with abnor-
mal expression of BM proteins, immunostaining for perle-
can (Fig. 2, N and O), laminin-1 (Fig. 2, P and Q), and col-
lagen IV (not shown) was performed on normal and
perlecan-null cardiac tissue. With the exception of perle-
can, all BM components were similarly expressed in mu-
tant tissue (Fig. 2, P and Q). These data demonstrate that
perlecan-deficient cardiac muscle cells lack BM or are cov-
ered by abnormal BM, which disrupts the integrity of the
myocardium and leads to the formation of small clefts in
myocardial tissue and finally to blood leakage into the
pericardial cavity.
 
Development of Exencephaly and Neuronal Ectopias
 
About 80% of the perlecan-null embryos surviving the
first crisis developed an exencephalic malformation that
 
Figure 2.
 
Development of the hemopericard in E10.5 perlecan-
null embryos. (A and B) Whole mount pictures of E10.5 wild-
type (A) and perlecan-deficient embryos showing blood leakage
into the pericardial cavity (B, arrow). (C–H) Light microscopy of
semi-thin sections of wild-type (C and E) and perlecan-null
hearts (D and F–H) stained with methylene blue. (C) Myocardial
wall with well developed trabeculation separated from the thin
pericardium by a cell-free cavity. (E) Higher magnification shows
that cardiomyocytes are covered by an endo- and epicardial cell
layer. (D) Myocardial wall of homozygotes is disrupted (arrow),
whereas the endo- and epicardial cell layers are intact. The peri-
cardial cavity contains blood cells and is surrounded by a thick-
ened pericardium. (F–H) Three different perlecan-null hearts
with small ruptures in the myocardial wall (arrows). (I–K) Elec-
tron microscopy of a normal (I) cardiac muscle cell with BM
composed of a lamina rara and densa (arrow). Mutant cardiac
muscle cell shows a typical myofilament organization but lacks a
BM (arrow in J) or with BM-like material (arrow in K) on the
cell surface. (L and M) Typical BM with a lamina rara and densa
(arrow) beneath the dermal epithelium of wild-type (L) and per-
lecan-null (M) embryos. (N-Q) Immunostaining for perlecan (N
and O) and laminin-1 (P and Q) of a wild-type (N and P) and per-
lecan-null (O and Q) heart. Perlecan is absent but laminin-1 is ex-
pressed in homozygous hearts. Abbreviations: v, ventricle; m,
myocardium; p, pericardium; mf, muscle filament; and e, epithe-
lial cell. Bars: (C and D) 250 
 
m
 
m; (E–H) 100 
 
m
 
m; (I–M) 250 nm;
and (N–Q) 250 
 
m
 
m. 
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was first visible between E10.5 and E11.5. To test whether
the absence of perlecan results in an abnormal closure of
the neural tube, scanning electron microscopy was per-
formed with normal and perlecan-null E10.5 embryos. All
normal (
 
n
 
 5 
 
3) and perlecan-null embryos (
 
n
 
 5 
 
11) ana-
lyzed, displayed properly closed neuropores (Fig. 3, A–C).
This was also confirmed by histological studies on E9.5
and E10.5 cephalic regions derived from mutant embryos
(not shown). Some perlecan-null embryos had holes in the
fore- and midbrain and showed collapsed brain vesicles
(Fig. 3 C). The cephalic region of normal embryos was
covered by an intact layer of ectodermal cells (Fig. 3 D).
However, at higher magnification, the surface ectoderm of
seven out of nine homozygotes showed small clefts that
were 20–30 
 
m
 
m in width that contained round cells with
small extensions (Fig. 3 E). In nullizygotes with severe de-
fects, round cells with small extensions traversed the ce-
phalic mesenchyme to reach the surface ectoderm (Fig. 3 F).
To exclude that the clefts were caused artificially during
embryo handling, heads were incubated with colloidal
gold-conjugated antibodies binding to laminin-1 (Fig. 3 G)
and analyzed by scanning electron microscopy. Prepara-
tion artefacts occurring after antibody incubation were de-
void of staining (Fig. 3, H and J, and arrow in I and K),
whereas clefts already present in homozygotes before han-
dling showed colloidal gold staining of the exposed BM
(Fig. 3, I and K).
Histological analysis of brain sections from normal and
perlecan-null E9.5 embryos revealed normal BM between
neural tissue and mesenchyme (not shown). At E11.5,
70% of homozygotes showed areas in which the BM sur-
rounding the telencephalic vesicles was disrupted (Fig. 4,
D and F), and the brain tissue had invaded into the cephalic
mesenchyme and fused with the overlaying ectoderm (Fig.
4 H). Immunostaining revealed that the ectopias con-
tained many nestin-positive cells (a marker for neuroepi-
thelial cells; Fig. 4, I and J), but lacked 
 
b
 
III isotype tubu-
lin-positive cells (a marker for committed neurons; Fig. 4,
K and L). In the ectopic region, the neuroepithelium ap-
peared thickened and the cells in the ventricular zone re-
gion were round instead of elongated as observed in the
neocortex of normal embryos (Fig. 4, G and H). At E11.5,
clusters of neuroepithelial cells were exposed to the amni-
otic cavity and formed small disruptions of 5–10 
 
m
 
m (Fig. 4
M). Immunostaining for proliferative cells with Ki-67 anti-
bodies and for apoptotic cells with TUNEL labeling re-
vealed no abnormalities in E10.5 and E11.5 perlecan-null
brain tissues, neither in ectopias nor in normal appearing
Figure 3. Scanning electron
microscopy revealed brain
defects in perlecan-null em-
bryos. (A–C) Scanning elec-
tron microscopy shows that
the neural tube is closed in
wild-type (A) and perlecan-
deficient (B and C) E10.5 em-
bryos. Some perlecan-null
embryos show holes (C, ar-
rows) in the fore- and mid-
brain and collapsed brain
vesicles. (D–F) High magnifi-
cation of the surface ecto-
derm. In wild-type embryos
(D), the cephalic region is
covered with an intact layer of
ectodermal cells. Perlecan-
null embryos (E) show small
clefts that are 20–30 mm in
width and contain round cells
with small extensions (arrow).
In other perlecan-deficient
embryos (F), round cells with
extensions burst through the
surface ectoderm (arrow). G
shows an antibody coupled to
colloidal gold reacting with
purified laminin. (H–K) Back-
scattered electron analysis
shows that small defects in the
ectoderm of normal mice
caused during the preparation
are not labeled with the gold-
conjugated antibody (second-
ary electron image H and
backscattered electron image J), while the clefts in perlecan-null embryos are labeled (secondary electron image I, backscattered elec-
tron image K). Arrow in K indicates an ectodermal defect caused during the preparation. Bars: (D–F and H–K) 20 mm; and (G) 50 nm. 
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areas of the neocortex (not shown). At later stages, several
homozygotes without obvious exencephaly showed a ruf-
fled brain surface because the marginal zone of the neo-
cortex was studded with large ectopias associated with a
severe distortion of the laminar architecture of the cortex
(Fig. 4, O and Q).
All perlecan-null embryos analyzed so far, including
those without exencephaly, exhibited neuronal ectopias
in the ventral telencephalic region of the brain, when ex-
amined at E11.5 and later stages (Fig. 5). The ectopias
appeared as small, compact clusters of 
 
b
 
III isotype tubu-
lin-positive cells (Fig. 5, A–F) that had invaded the mesen-
chyme (Fig. 5, B, D, F, H, J, and L) at areas where the
basement membrane is disrupted as shown by immu-
nostaining for laminin-1 (Fig. 5, I and J). Immunostaining
for laminin-1 and perlecan at E13.5 revealed that both
molecules were expressed around brain vessels and in the
leptomeninges surrounding the brain tissue (Fig. 5, I and
K). No perlecan expression was found in the brain paren-
chyma of normal mice (Fig. 5 K).
 
Chondrodysplasia Associated with Abnormal 
Endochondral Ossification
 
All perlecan-null embryos that did not exhibit apparent
heart defects continued their intrauterine development
but died perinatally. Between E15 and the newborn stage,
these animals developed a severe osteochondrodysplasia
characterized by dwarfism, cleft palate, short limbs, and a
 
Figure 4.
 
Exencephaly and neuronal ectopias develop in the an-
terior region of the forebrain. (A and B) Hematoxylin/eosin
staining of sagittal brain sections from wild-type (A) and perle-
can-null (B) E11.5 embryos. Note the extension and the thinning
of the anterior part of the forebrain in the perlecan-null embryo
(upper box in B). Ectopias are visible ventral of the medial gan-
glionic eminence (arrow) in the homozygous embryo. (C–F)
Higher magnification of the lower boxes indicated in A and B. In
a normal brain, the neuroepithelium and the underlying mesen-
chyme are separated by a BM (C) that contains laminin-1 (E). In
the perlecan-null brain, the BM is discontinuous (D, arrow) and
shows interrupted laminin-1 staining (F, arrow). (G and H)
Higher magnification of the upper boxes indicated in A and B. In
a normal brain, the neuroepithelium and the overlying mesen-
chyme are separated by a BM (G). In the perlecan-null brain,
neuroepithelial cells have invaded the overlying ectoderm (H,
arrow). (I–L) Immunohistochemical localization of nestin and
 
b
 
-tubulin type III in the neocortex of normal and perlecan-null
embryos. The neocortex of the wild-type embryo contains nestin-
positive cells (I) and a few 
 
b
 
-tubulin type III–positive cells in the
cortical subplate (K). Ectopic cells in the perlecan-null embryo
are positive for nestin (J) but negative for 
 
b
 
-tubulin type III (L).
(M) Hematoxylin/eosin staining of the forebrain region of an
E11.5 homozygote showing a defect in the ectoderm and a small
hole of 5–10 
 
m
 
m (arrow). Note that the amniotic membrane is
still intact (arrowhead). (N–Q) Nissl staining of coronal sections
of wild-type (N and P) and perlecan-null (O and Q) E17.5 fore-
brain regions. The perlecan-null brain shows a ruffled surface,
large ectopias, and abnormal lamination (O). Posterior to this
area, the ruffles and defects in lamination are less severe (Q).
Abbreviations: mz, marginal zone; cp, cortical plate; iz, interme-
diate zone; and vz, ventricular zone. Bars: (C–L) 125 
 
m
 
m; (M) 250
 
m
 
m; and (N–Q) 500 
 
m
 
m. 
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short and abnormally bended vertebral column (Fig. 6 A
and not shown). Approximately 80% of homozygotes had
exencephaly and lacked calvarial bones (Fig. 6 A, 2/2b).
Homozygotes without exencephaly had a domed skull
(Fig. 6 A, 2/2a). Whole mount skeletons of E17.5 em-
bryos showed that all bones were present in perlecan-null
embryos, except in exencephalic embryos, which lacked
frontal and parietal bones (Fig. 6 B, 2/2a and 2/2b). De-
tailed inspection of the mutant skeleton showed that long
bones were approximately half of the size of wild-types. In
addition, the cortical bone was thickened. In the skull, the
mandible and nasal bone were shortened, and the struc-
tures of the middle and inner ear were poorly developed
(Fig. 6 B). The bones of chondrocranium (occipital, sphe-
noidal, and ethmoidal) were shortened and undermineral-
ized (data not shown).
Histological analysis at various stages of development
revealed that the cartilage anlage of all long bones oc-
curred normally in the mutant mice (not shown). Between
E13 and 14, the first alterations in size and shape of the
perlecan-null long bones became apparent (Fig. 6, C and
D). Mutant bones had disorganized growth plates charac-
terized by the absence of the typical columnar arrange-
ment of hypertrophic chondrocytes. In addition, hyper-
trophic chondrocytes showed an atypical morphology, and
growth plates were always dissociated from their epiphy-
ses (Fig. 6 F). Such gaps in the tissue were never observed
in normal bones and, therefore, suggest a mechanical
weakness of the mutant cartilage leading to damage dur-
ing tissue processing. Perlecan-null bones had small mar-
row cavities.
Impaired Mineralization and Reduced
Collagen Content
Safranin-O staining was reduced in perlecan-null cartilage,
suggesting a decreased proteoglycan content (Fig. 7, A
and B). van Kossa staining revealed that normal bones
showed clear mineralization in the longitudinal septa of
the late hypertrophic zone (Fig. 7 A), perlecan-null tissue
had minimal or no mineral deposits in the matrix around
hypertrophic chondrocytes, and the calcified trabecula
were transversely oriented in perlecan-null bones (Fig. 7
B). Immunohistochemistry showed expression of perlecan
in cartilage as well as the surrounding mesenchyme of nor-
mal but not mutant mice (Fig. 7, C and D). Matrix proteins
including collagen types II, IX, X, and XI, aggrecan, matri-
lin-1 and -3, and COMP were expressed in homozygotes
(Fig. 7, F and H, and not shown).
The ultrastructure of cartilage tissue derived from an
Figure 5. Neuronal ectopias in the ventral forebrain. (A–D) He-
matoxylin/eosin staining of coronal brain sections from wild-type
(A and C) and perlecan-null (B and D) E12.5 embryos. Ectopias
(B and D, arrows) are visible in the ventral forebrain of homozy-
gotes. (E and F) Cells within the ectopias are b-tubulin type III–
positive (F, arrow). (G–L) Hematoxylin/eosin and immunostain-
ing of sagittal brain sections from wild-type (G, I, and K) and
perlecan-null (H, J, and L) E13.5 embryos. Ectopias (H, J, and L,
arrows) are visible in the ventral forebrain. Laminin-1 is ex-
pressed in the leptomeninges and around the capillaries in both
the wild-type (I) and perlecan-null (J) brain. In homozygotes,
laminin-1 staining is disrupted around the ectopias (arrows). Per-
lecan is expressed around capillaries and in the leptomeninges
but not in brain of normal embryos (K). No perlecan staining is
detectable in homozygotes (L). Bars: (C–F and I–L) 250 mm.Costell et al. Perlecan-null Mouse 1117
E17.5 limb showed that wild-type hypertrophic chondro-
cytes were electron lucent with a paucity of organelles in
the cytosol (Fig. 8, A and C). The wild-type chondrocytes
also showed contacts with the surrounding matrix that was
homogeneously filled with fibrillar collagen (Fig. 8 A). In
contrast, hypertrophic chondrocytes of perlecan-null mice
displayed an increased density of organelles and distended
cisternae of ER (Fig. 8, B and D). The cytosol was en-
riched with free ribosomes and polysomes (Fig. 8 D, ar-
rowheads). The collagen fibrils in wild-type growth plate
cartilage showed a random distribution, had uniform
length and diameter, and formed a typical network (Fig. 8
E). The perlecan-null growth plate cartilage lacked such
collagen network and the fibrils were shorter in length
(Fig. 8 F).
To test whether an increased expression of cartilage
ECM genes was responsible for the high metabolic activity
in perlecan-null chondrocytes, Northern assays were per-
formed with the total RNA derived from cartilage of nor-
mal and homozygous E18 limbs. Analysis of optical densi-
Figure 6. Skeletal abnormal-
ities in perlecan-null em-
bryos. (A) Lateral view of
E16.5 normal, heterozygous,
and perlecan-null (2/2a and
2/2b) embryos. Loss of per-
lecan results in dispropor-
tionate dwarfism with short
limbs, neck, and snout. Some
homozygotes have domed
skull (2/2a), others lack the
roof of skull and exhibit ex-
encephaly (2/2b). (B) Al-
cian blue/alizarin red stained
skeletons of normal, heterozy-
gous, and perlecan-null (2/2a
and  2/2b) E17.5 embryos.
The skeleton of heterozy-
gotes is normal. The spine of
homozygous mutants is short
and displays severe ky-
phoscoliosis, the thorax is
narrow, and the ribs, verte-
brae, and long bones are mal-
formed. Embryos with exen-
cephaly (2/2b) lack frontal
and parietal bones of the
skull. (C–F) Comparative
histological analysis of devel-
oping hindlimbs from normal
(C and E) and homozygotes
(D and F). Sagittal sections
from E14 (C and D) and
E16.5 (E and F) embryos
stained with hematoxylin/
eosin. At E14, the mutant
tibia (ti) and fibula (fi) are
short, thick, and curved (D).
At E16.5, the mutant tibia
(F) is short and thick, the
metaphyseal bone is ex-
tremely reduced, and the
growth plate is disorganized.
Abbreviations: ec, epiphy-
seal cartilage; p, zone of pro-
liferative chondrocytes; h,
zone of hypertrophic chon-
drocytes; and bc, bone cavity.
Bar: (C–F) 100 mm.The Journal of Cell Biology, Volume 147, 1999 1118
ties of mRNA signals such as shown in Fig. 8 G revealed
that Col2a1 expression was increased threefold, and matri-
lin-3 and COMP expression was increased fivefold in mu-
tant cartilage.
Discussion
We have generated perlecan-deficient mice, and we dem-
onstrate that perlecan is essential for embryonic develop-
ment. It plays a major role for maintaining the integrity of
basement membranes and cartilage matrix, but has no ap-
parently critical function in basement membrane assem-
bly, organogenesis, and mesenchymal cell migration.
Early Embryonic Development Is Not Affected by the 
Loss of Perlecan
Perlecan is expressed throughout development. In the pre-
implantation period, it is found between blastomeres and
on the external trophectodermal cell surface of blastocysts
just before they become attachment-competent, suggest-
ing that embryo-derived perlecan initiates implantation by
attaching embryos to the uterine epithelium (Smith et al.,
1997). Our results do not confirm such a role for perlecan.
We found neither a delayed nor a reduced implantation
rate of perlecan-null embryos, and the Mendelian distribu-
tion of genotypes was normal at all stages analyzed be-
tween E5.5 and E9.5. Perlecan was also thought to be im-
portant for BM assembly and function (Timpl, 1993; Timpl
and Brown, 1996). These complex and highly ordered BM
structures are composed of many constituents and serve as
barriers, substratum for epithelial sheets, and sinks for
growth factor storage and release (Timpl and Brown,
1996). Despite the ability of perlecan to interact with sev-
eral BM components, adhesion molecules involved in BM
assembly, and growth factors (Timpl, 1993; Timpl and
Brown, 1996), all BMs form in the absence of perlecan and
appear morphologically normal. A likely explanation for
this finding is that other heparan sulfate proteoglycans
substitute for the loss of perlecan and the glycosaminogly-
can chains attached to it. A possible candidate is ag-
rin, which is present in most if not all BMs and can also
bind growth factors, a-dystroglycan and BM components
(Ruegg and Bixby, 1998). Mice lacking the neuronal splice
Figure 7. ECM expression in
long bones. (A and B) Safra-
nin orange (SO) and van
Kossa (vK) double staining
show reduced proteoglycan
content in mutant (B) as
compared with wild-type (A)
cartilage and the absence of
mineralization of longitudi-
nal septa in the lower hyper-
trophic zone (1 h) of the mu-
tant growth plate (A and B).
Also, note the transversally
oriented trabecular bones in
the mutant (arrows). (C–H)
Immunostaining of perlecan
and collagen types II (Col2)
and X (Col10) on consecutive
sections of elbows from nor-
mal and perlecan-null E15.5
embryos. Perlecan is present
in normal cartilage, in the pe-
riosteum/perichondrium, and
in the surrounding connec-
tive tissues (C). In mutant
embryos, perlecan staining is
absent (D). The distribution
of collagen types II (E and F)
and X (G and H) is similar in
normal (E and G) and perle-
can-null (F and H) cartilage.
Bar: (A–D and G and H) 100
mm; 50 mm in E and F.Costell et al. Perlecan-null Mouse 1119
variant of agrin have defects in neuromuscular synapto-
genesis but are otherwise apparently normal (Gautam et
al., 1996). The lack of a general phenotype in these mu-
tants could be due to the very low expression of nonneu-
ronal agrin or the functional substitution by perlecan.
Perlecan is Essential for Maintaining Myocardial 
Basement Membranes and Heart Function
At E9.5 all perlecan-null embryos analyzed were of nor-
mal size, had similar pulse rates to their wild-type and het-
erozygous littermates, and showed no histological abnor-
malities. Between E10.5 and E12.5, z70–80% of the
perlecan-null embryos died. When alive homozygotes
were dissected, their hearts were of normal size and
shaped with a well developed myocardium that was lined
by endocardium internally and epicardium externally.
However, the ventricles were suffused with blood leakage
into the pericardial cavity. Cardiac muscle cells that nor-
mally differentiate at around E7.5–E8, form intercalated
discs (Challice and Viragh, 1973) and an immature BM on
the free cell surface (Kitten et al., 1987). Their contrac-
tions are initially arrhythmic, but at around E9 they con-
tract regularly and with high frequency. The intraventricu-
lar pressure significantly rises in the developing chicken
heart between embryonic day 5 and 6 (Faber, 1968), which
corresponds to E10–12 in mouse. At around E9, a thin but
distinct BM had formed on cardiac muscle cells in normal
and perlecan-null mice. In all perlecan-null embryos with
hemopericardium, however, this BM had deteriorated. At
E10.5, we observed small clefts in the myocardium that
were often still lined by endocardium and epicardium. Ul-
trastructural analysis revealed striking abnormalities in
their BMs. Either the lamina densa was completely absent
or the cell surface was sparsely covered by densities of ir-
regular shape and size. These alterations could be ob-
served throughout the mutant hearts and were not re-
stricted to the defects in the myocardium. Furthermore,
some cardiomyocytes were lined by partly normal and
partly abnormal BMs. Interestingly, the homozygotes that
survived the E10.5 crisis also showed the same BM defect
in their hearts. We further confirmed this defect by cross-
ing homozygotes with a transgenic strain expressing the
green fluorescence protein under the control of the car-
diac actin promoter (Fleischmann et al., 1998). When
rhodamine-labeled dextran was injected into the atrium of
such embryos using the patch clamp technique to control
volume and pressure, the cardiac muscle wall of z70% of
the homozygous embryos showed two to five leaking
transmural channels, and the remaining 30% began to leak
when the injection pressure was slightly increased to a
level tolerated in normal or heterozygous control hearts
(Bloch, N., unpublished observation). At present, we do
not know why the heart of these surviving homozygotes
does not develop holes in the myocardium. A likely explana-
tion is that cell–cell contacts such as intercalated discs, which
were normal in affected and unaffected homozygotes, suffi-
ciently compensate for the BM defects. Altogether, our find-
ings suggest that loss of perlecan is not crucial for the assem-
bly of BMs on early contracting cardiomyocytes but for the
maintenance of their structural and functional integrity
when subjected to mechanical stress.
Perlecan Is Required for Normal Brain Development
All perlecan-null embryos that survive the first crisis de-
velop brain anomalies. This was unexpected since we and
others found no perlecan expression in the central nervous
system (Handler et al., 1997). We used different polyclonal
Figure 8. Ultrastructure of hypertrophic chondrocytes and terri-
torial matrix. (A and C) The hypertrophic chondrocyte in a nor-
mal mouse femur has low organelle density. The septa are homo-
geneously filled with fibrillar collagen (arrows) and calcified
material (c). (B and D) The hypertrophic chondrocyte in a perle-
can-null femur displays increased density of organelles, and the
cytosol is highly enriched with free ribosomes and polysomes (ar-
rowheads). The adjacent pericellular matrix compartment is
filled with fibrillar collagen but lacks calcification. (E and F) The
territorial zone in normal cartilage shows random distribution of
collagen fibrils. The collagen fibrils are of uniform diameter and
length (E). The territorial zone in homozygotes lacks a well orga-
nized collagen fibrillar network. The collagen fibrils are shorter
in length, lower in contrast, and the density is reduced. (G) The
expression of Col2a1, matrilin-3, and COMP mRNA is increased
in perlecan-deficient cartilage. Abbreviations: P, plasma mem-
brane; N, cell nucleus; and C, calcification. Bars: (A and B) 5 mm;
1 mm (C and D); and (E and F) 0.5 mm.The Journal of Cell Biology, Volume 147, 1999 1120
antibodies raised against domains I, III, and V of perlecan
that revealed expression in the choroid plexus, the suben-
dothelial BMs, and in the BM surrounding the brain.
The brain defects were first visible at E10.5 in the ante-
rior region of the expanding brain vesicle. At this stage,
two well developed BMs separate the ectoderm and the
brain tissue from the mesenchyme. The disruption of both
BMs caused aberrant fusion of brain tissue with the over-
lying ectoderm. Using EM scanning, the BM defects ap-
peared as small clefts, usually not .20–30 mm in width,
which contained small round cells. This type of defect ex-
posed brain tissue to amniotic fluid, which led to the de-
struction of the tissue and the development of exencephaly.
Exencephaly can result from defects in neural tube clo-
sure, abnormal neuronal migration, or altered prolifera-
tion and/or apoptosis of neurons or neuronal precursor
cells. We did not observe any of these three defects in per-
lecan-null embryos. All embryos analyzed by electron or
light microscopy showed normal closure of the neural
tube, and we could not find abnormal rates of neuronal
proliferation and apoptosis in the expanding brain vesicles
and other regions of the developing brain before, or at the
time of, the onset of defects. When the exencephaly was
fully developed we saw increased proliferation of neuronal
and glial cells in some of the mutant brains that, however,
may be a secondary effect of the amniotic fluid on brain
cells. Finally, we found no evidence of abnormal neuronal
migration as the cause of the exencephaly. The earliest
neuronal cells born in the forebrain are Cajal-Retzius neu-
rons and the subplate neurons that start to migrate at
around E9.5-E10 (Derer and Derer, 1990). Most other
neurons start to migrate around E12 from the ventricular
zone along the radial glia to form the typical laminae of
the cortex (Rakic, 1995). The cells in the affected brain ar-
eas of perlecan-null embryos expressed neither reelin nor
other neuronal markers such as bIII tubulin but stained
strongly for nestin, suggesting that they are neuroepithe-
lial cells.
It was shown in earlier studies that the intraventricular
pressure in the developing brain is much higher than the
pressure in the amniotic cavity (Jelinek and Pexieder,
1968). In chick embryos, it was demonstrated that the re-
lease of the intraventricular pressure leads to the collapse
of the brain vesicles and to the formation of ruffles (Des-
mond and Jacobson, 1977) similar to that seen in the perle-
can-null brains. We observed that the disruptions in BMs
occurred always in the polar area of the brain vesicles
where the brain tissue is thin and, therefore, most vulnera-
ble to the vesicular pressure and before the expansion of
the neuroepithelium. Therefore, these data suggest that
perlecan maintains BM stability by withstanding the ten-
sile force exerted by the expanding brain vesicles. Since
the BM has an important barrier function, particularly
during development, where tissues are constantly remod-
eled, small gaps in the BM can lead to an abnormal expan-
sion of neuroepithelial cells and eventually to tissue fu-
sion. A similar process has been observed in mice lacking
the laminin a5 chain, which develop small gaps in the BM
of the developing hind buds, allowing mesenchymal cells
to invade the overlaying ectoderm and eventuating in syn-
dactyly (Miner et al., 1998).
In addition to the exencephaly, all perlecan-null em-
bryos developed small neuronal ectopias ventral to the
medial ganglionic eminence in the developing forebrain.
These ectopias that were first visible at E11.5, maintained
a constant size and contained postmitotic neuronal cells.
Similarly, as on the surface of the brain vesicle, the cells
had migrated through the disrupted BM and invaded the
surrounding mesenchyme. At present, we are not sure why
these neurons fail to stop their migration. It is probable
that the migrating neurons exert mechanical stress on the
perlecan-null BM, which leads to small gaps allowing cells
to invade the mesenchyme. The BM had small gaps that
were very similar to those found on the surface of the
brain vesicles and the ectopias were always found at the
same location, i.e., ventral to the ganglion eminence where
active remodeling, extensive migration, and expansion of
cells is occurring. The surrounding mesenchyme, being a
mechanically resilient tissue, would physically prevent the
further aberrant migration of these neurons.
Perlecan Supports Endochondral Ossification by 
Maintaining the Cartilage ECM
All perlecan-null embryos surviving the first critical period
between E10 and E12.5 develop chondrodysplasia charac-
terized by disproportionate dwarfism, disorganization of
the growth plate, cleft palate, and perinatal lethality most
probably because of respiratory failure. During mouse de-
velopment, perlecan mRNA is expressed in the precarti-
laginous tissues, accumulates until E14–E15 in all cartilage
primordia, and then sharply decreases to background level
(Handler et al., 1997, French et al., 1999). However, perle-
can expression is not detectable in membranous bones
(French et al., 1999). Despite the abundant deposition of
perlecan in cartilage, its function during skeletal develop-
ment is speculative and mainly based on in vitro experi-
ments. French et al. (1999) demonstrated recently that
10T1/2 cells efficiently aggregate into dense cartilaginous
nodules when cultured on perlecan, suggesting that perle-
can promotes chondrogenic differentiation. We find that
the cartilaginous analogue forms normally in perlecan-null
mice, indicating that perlecan is not essential for the con-
densation and differentiation of prechondrogenic mesen-
chyme into cartilaginous blastema.
During endochondral ossification, the formation of the
cartilage model is followed by a complex process that in-
cludes the further differentiation of chondrocytes, matrix
calcification, vascularization, and the replacement of carti-
lage by bone (Horton, 1993). In long bones, endochondral
ossification takes place mainly in the epiphyseal growth
plate. The perlecan-null bones showed mild changes in epi-
physeal cartilage but severe abnormalities in the growth
plate, suggesting that perlecan is important for its proper
organization and function. Since the perlecan-null chon-
drocytes can undergo an apparently normal differentiation
cascade characterized by the synthesis of lineage-specific
matrix components such as type X collagen and of other
differentiation genes such as BMP2, Sox9, and indian
hedgehog (Aszódi, A., unpublished observation), these ab-
normalities are apparently not associated with an altered
chondrocyte differentiation or maturation. In addition to
the growth plate abnormalities, perlecan-null long bones
exhibit a bended shape. The shape deformation beginsCostell et al. Perlecan-null Mouse 1121
shortly after the differentiation of hypertrophic chondro-
cytes. This finding might be explained by the abnormal
hypertrophic matrix, which has a decreased resistance
against mechanical forces arising from muscle contraction.
Interestingly, the skeletal abnormalities observed in the
perlecan-null mice resemble the phenotype of Col2a1-
deficient mice (Aszódi et al., 1998) and Dmm (dispropor-
tionate micromelia) mice that carry a three-nucleotide de-
letion in the C-propeptide coding region of the Col2a1
gene, resulting in a severe reduction of type II collagen fi-
ber network in cartilage (Pace et al., 1997). Like in Col2a1-
null or Dmm mice, the cartilage of perlecan-null mice is
very soft and structurally disorganized. The long bones are
shortened and thickened and the bony trabecula are ori-
ented transversely to the long axis. The reduced Safra-
nin-O staining of cartilage and the almost complete lack of
mineralization in the late hypertrophic zone is observed in
both perlecan-null and Col2a1-null mice. Surprisingly, the
ultrastructural analysis of perlecan-null cartilage revealed
a lack of the typical collagen network. The reduced
amount and the shortening of collagen fibrils suggests that
perlecan plays a pivotal role in maintaining the collagen
network. In contrast to the reduced collagen fibrils, the
EM analysis revealed a dilated ER and a tremendous in-
crease in free ribosomes and polysomes in the cytosol of
chondrocytes, which indicates an unusually high biosyn-
thetic activity in perlecan-null chondrocytes. This was fur-
ther supported by Northern analysis showing that cartilage
tissue derived from perlecan-null embryos expressed three
to five times more mRNA coding for Col2a1, matrilin-3,
and COMP. Apparently, perlecan-null chondrocytes try to
compensate for the loss of cartilage ECM by increasing its
synthesis. Since the de novo synthesis does not compen-
sate for the disintegrated matrix, the growth plates deteri-
orate and are unable to lay down a calcified matrix in the
hypertrophic zone leading to insufficient endochondral os-
sification (template for endochondral bone). These exper-
imental findings revealed a new function of perlecan
during  endochondral bone formation. A mechanistical ex-
planation could be that perlecan protects the cartilage
ECM possibly by binding and inactivating tissue proteases
or by masking the ECM proteins and, hence, protecting
them from protease attack. Interestingly, it has been
shown that perlecan inhibits the proteolytic degradation of
fibrillar Ab (Gupta-Bansal et al., 1995), which is thought
to play an important role for the accumulation and persis-
tence of neurotoxic plaques in Alzheimer’s disease. It is
conceivable that similar mechanisms are responsible for
the inhibition of proteolysis by perlecan in developing car-
tilage and Alzheimer’s disease.
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